Free Trial
NASDAQ:LAB

Standard BioTools (LAB) Stock Price, News & Analysis

Standard BioTools logo
$1.96
+0.08 (+4.26%)
(As of 10/31/2024 ET)

About Standard BioTools Stock (NASDAQ:LAB)

Key Stats

Today's Range
$1.93
$2.26
50-Day Range
$1.68
$2.18
52-Week Range
$1.21
$3.04
Volume
4.63 million shs
Average Volume
2.47 million shs
Market Capitalization
$727.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Standard BioTools Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

LAB MarketRank™: 

Standard BioTools scored higher than 53% of companies evaluated by MarketBeat, and ranked 585th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Standard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Standard BioTools has only been the subject of 1 research reports in the past 90 days.

  • Read more about Standard BioTools' stock forecast and price target.
  • Earnings Growth

    Earnings for Standard BioTools are expected to grow in the coming year, from ($0.42) to ($0.30) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Standard BioTools is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Standard BioTools is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Standard BioTools' valuation and earnings.
  • Percentage of Shares Shorted

    5.94% of the float of Standard BioTools has been sold short.
  • Short Interest Ratio / Days to Cover

    Standard BioTools has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Standard BioTools has recently increased by 0.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Standard BioTools does not currently pay a dividend.

  • Dividend Growth

    Standard BioTools does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.94% of the float of Standard BioTools has been sold short.
  • Short Interest Ratio / Days to Cover

    Standard BioTools has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Standard BioTools has recently increased by 0.19%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Standard BioTools has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Standard BioTools this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,662,080.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Standard BioTools' insider trading history.
Receive LAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

LAB Stock News Headlines

Standard BioTools Reports Third Quarter 2024 Financial Results
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

LAB Stock Analysis - Frequently Asked Questions

Standard BioTools' stock was trading at $2.21 at the beginning of 2024. Since then, LAB stock has decreased by 11.3% and is now trading at $1.96.
View the best growth stocks for 2024 here
.

Standard BioTools Inc. (NASDAQ:LAB) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05. The business had revenue of $44.97 million for the quarter, compared to analyst estimates of $42 million. Standard BioTools had a negative trailing twelve-month return on equity of 43.45% and a negative net margin of 87.05%.

Standard BioTools' top institutional shareholders include SG Americas Securities LLC (0.03%), Creative Planning (0.01%) and Nisa Investment Advisors LLC. Insiders that own company stock include Casdin Partners Master Fund, L and Caligan Partners Lp.
View institutional ownership trends
.

Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
10/30/2024
Today
10/31/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:LAB
Employees
620
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.88
High Stock Price Target
$3.25
Low Stock Price Target
$2.50
Potential Upside/Downside
+53.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-74,660,000.00
Pretax Margin
-87.00%

Debt

Sales & Book Value

Annual Sales
$136.30 million
Book Value
($1.85) per share

Miscellaneous

Free Float
174,071,000
Market Cap
$727.46 million
Optionable
Optionable
Beta
1.58
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:LAB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners